Trial · NCT00926380
Adverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 21
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash | Skin and subcutaneous tissue disorders | Denosumab ONLY | 4 | 33 | |
| other | Rash | Skin and subcutaneous tissue disorders | Teriparatide (Forteo®) ONLY | 0 | 31 | |
| other | Rash | Skin and subcutaneous tissue disorders | Denosumab and Teriparatide (Forteo®) | 2 | 30 | |
| other | Reactions at injection site | Skin and subcutaneous tissue disorders | Denosumab ONLY | 0 | 33 | |
| other | Reactions at injection site | Skin and subcutaneous tissue disorders | Teriparatide (Forteo®) ONLY | 2 | 31 | |
| other | Reactions at injection site | Skin and subcutaneous tissue disorders | Denosumab and Teriparatide (Forteo®) | 0 | 30 | |
| other | Hypercalcemia | Endocrine disorders | Denosumab ONLY | 0 | 33 | |
| other | Hypercalcemia | Endocrine disorders | Teriparatide (Forteo®) ONLY | 0 | 31 | |
| other | Hypercalcemia | Endocrine disorders | Denosumab and Teriparatide (Forteo®) | 2 | 30 | |
| other | Nausea | Gastrointestinal disorders | Denosumab ONLY | 0 | 33 | |
| other | Nausea | Gastrointestinal disorders | Teriparatide (Forteo®) ONLY | 3 | 31 | |
| other | Nausea | Gastrointestinal disorders | Denosumab and Teriparatide (Forteo®) | 0 | 30 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Denosumab ONLY | 1 | 33 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Teriparatide (Forteo®) ONLY | 1 | 31 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Denosumab and Teriparatide (Forteo®) | 0 | 30 | |
| serious | Melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Denosumab ONLY | 0 | 33 | |
| serious | Melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Teriparatide (Forteo®) ONLY | 0 | 31 | |
| serious | Melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Denosumab and Teriparatide (Forteo®) | 1 | 30 | |
| serious | Heart attack | Cardiac disorders | Denosumab ONLY | 0 | 33 | |
| serious | Heart attack | Cardiac disorders | Teriparatide (Forteo®) ONLY | 1 | 31 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00926380/events